Ireland - English - HPRA (Health Products Regulatory Authority)

sol s.p.a. - nitrous oxide - medicinal gas, liquefied - 100 percent volume/volume - other general anesthetics; nitrous oxide

Singapore - English - HSA (Health Sciences Authority)

viatris private limited - celecoxib - capsule - 100 mg - celecoxib 100 mg

Canada - English - Health Canada

mcneil consumer healthcare division of johnson & johnson inc - ibuprofen - tablet - 100mg - ibuprofen 100mg - other nonsteroidal antiimflammatory agents

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ciprofloxacin, quantity: 100 mg - injection, solution - excipient ingredients: lactic acid; hydrochloric acid; water for injections; glucose monohydrate - ciprofloxacin injection for intravenous infusion is indicated for use in the following: 1. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. 2. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems: - lower respiratory tract infections (gram-negative organisms). skin and skin structure. septicaemia. bone and joint. urinary tract. 3. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram positive infections due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.

Israel - English - Ministry of Health

unipharm ltd, israel - tinidazole - tablets - tinidazole 500 mg - tinidazole - for the oral treatment of trichomonas vaginals infections of the genito urinary tract in both female and male. for the prevention of anerobic infections after gynocological operations and stomach operations.

Israel - English - Ministry of Health

unipharm ltd, israel - tinidazole - tablets - tinidazole 500 mg - tinidazole - tinidazole - for the oral treatment of trichomonas vaginals infections of the genito urinary tract in both female and male. for the prevention of anerobic infections after gynocological operations and stomach operations.

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - quetiapine fumarate (unii: 2s3pl1b6uj) (quetiapine - unii:bgl0jsy5si) - quetiapine 400 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ciprofloxacin -

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ciprofloxacin -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ciprofloxacin -